Intravitreal bevacizumab for filtering surgery.
BACKGROUND
It was the aim of this study to report on the intravitreal use of bevacizumab as antiproliferative agent in combination with filtering surgery.


METHODS
The clinical interventional case series study included 2 patients (2 eyes) who underwent standard antiglaucomatous penetrating filtering surgery combined with an intravitreal application of 1.5 mg bevacizumab. The intraocular pressure was elevated due to an intravitreal triamcinolone injection as treatment of exudative age-related macular degeneration (patient No. 1) or due to neovascular glaucoma (patient No. 2) after an ischemic retinal branch vein occlusion.


RESULTS
At 4 and 12 weeks after surgery, intraocular pressure was reduced in both patients to 10 and 14 mm Hg with functioning filtering blebs.


CONCLUSIONS
Intravitreal bevacizumab may potentially be helpful as addition to antiglaucomatous filtering surgery, particularly in neovascular glaucoma.
Jonas
Jost B
JB
Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany. jost.jonas@augen.ma.uni-heidelberg.de
Spandau
Ulrich H
UH
Schlichtenbrede
Frank
F
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D018463:Filtering Surgery; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D008297:Male; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab